RayKnowChina Research Map
Shortlist

Cancer

Nasopharyngeal carcinoma

鼻咽癌NPC

A cancer that starts in the lining of the nasopharynx. It is most common in Southeast Asian populations and is associated with Epstein–Barr virus infection.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
183

with a paper from 2016–2025 or a registered study

cities
69

where those hospitals are

open trials in China
168

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 76% of the world's English-language research papers on nasopharyngeal carcinoma, 2021–2025 (67% in 2016–2020), and 52% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

183 hospitals in 69 cities

Order: papers led on nasopharyngeal carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 3 papers or 1 trial on nasopharyngeal carcinoma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Guangzhou24
  2. Shanghai10
  3. Hangzhou8
  4. Shenzhen8
  5. Beijing6
  6. Changsha6
  7. Chongqing6
  8. Wuhan6
  9. Chengdu5
  10. Fuzhou5

Each opens nasopharyngeal carcinoma in that city. 59 more cities are in the menu below.

  1. 483 papers led
  2. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    87 papers led
  3. Xiangya Hospital

    中南大学湘雅医院Changsha

    63 papers led
    No open trial led
  4. 54 papers led
  5. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    53 papers led
  6. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    48 papers led
  7. 44 papers led
  8. 38 papers led
  9. 35 papers led
    No open trial led
  10. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    33 papers led
  11. 33 papers led
  12. Eye & ENT Hospital of Fudan University

    复旦大学附属眼耳鼻喉科医院Shanghai

    32 papers led
  13. 29 papers led
  14. 27 papers led
  15. 26 papers led
  16. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    25 papers led
  17. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    25 papers led
    No open trial led
  18. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    25 papers led
  19. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    25 papers led
  20. 21 papers led
    No open trial led
  21. 20 papers led
  22. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    19 papers led
    No open trial led
  23. 19 papers led
  24. 18 papers led
  25. 17 papers led
    No open trial led
  26. 16 papers led
    No open trial led
  27. 15 papers led
    No open trial led
  28. 15 papers led
    No open trial led
  29. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    14 papers led
  30. 14 papers led
  31. 14 papers led
  32. 14 papers led
    No open trial led
  33. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    14 papers led
  34. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    14 papers led
  35. 14 papers led
    No open trial led
  36. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    13 papers led
    No open trial led
  37. 13 papers led
    No open trial led
  38. 12 papers led
    No open trial led
  39. 11 papers led
    No open trial led
  40. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    11 papers led
    No open trial led
  41. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    11 papers led
  42. 11 papers led
    No open trial led
  43. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    11 papers led
    No open trial led
  44. 10 papers led
    No open trial led
  45. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    9 papers led
    No open trial led
  46. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    9 papers led
    No open trial led
  47. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    8 papers led
    No open trial led
  48. 8 papers led
    No open trial led
  49. 8 papers led
    No open trial led
  50. 8 papers led
    No open trial led
  51. 8 papers led
    No open trial led
  52. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    8 papers led
    No open trial led
  53. 8 papers led
    No open trial led
  54. 8 papers led
  55. 8 papers led
    No open trial led
  56. 8 papers led
    No open trial led
  57. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    8 papers led
    No open trial led
  58. 7 papers led
    No open trial led
  59. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    7 papers led
    No open trial led
  60. Integrated Hospital, Southern Medical University

    南方医科大学中西医结合医院Guangzhou

    7 papers led
    No open trial led
  61. 7 papers led
    No open trial led
  62. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    6 papers led
    No open trial led
  63. 6 papers led
    No open trial led
  64. 6 papers led
    No open trial led
  65. 6 papers led
    No open trial led
  66. 6 papers led
    No open trial led
  67. 6 papers led
    No open trial led
  68. First People's Hospital of Foshan

    佛山市第一人民医院Foshan

    6 papers led
    No open trial led
  69. 6 papers led
    No open trial led
  70. 5 papers led
    No open trial led
  71. 5 papers led
    No open trial led
  72. 5 papers led
    No open trial led
  73. 5 papers led
    No open trial led
  74. 5 papers led
    No open trial led
  75. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    5 papers led
    No open trial led
  76. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    5 papers led
    No open trial led
  77. 5 papers led
    No open trial led
  78. Hainan Cancer Hospital

    海南省肿瘤医院Haikou

    5 papers led
    No open trial led
  79. 5 papers led
    No open trial led
  80. Shanghai General Hospital

    上海市第一人民医院Shanghai

    5 papers led
    No open trial led
  81. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    5 papers led
    No open trial led
  82. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    5 papers led
    No open trial led
  83. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    5 papers led
    No open trial led
  84. Xijing Hospital

    空军军医大学西京医院Xi'an

    5 papers led
  85. 5 papers led
  86. 4 papers led
    No open trial led
  87. 4 papers led
    No open trial led
  88. 4 papers led
    No open trial led
  89. 4 papers led
    No open trial led
  90. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    4 papers led
    No open trial led
  91. 4 papers led
    No open trial led
  92. Nanyang First People's Hospital

    南阳市第一人民医院Nanyang

    4 papers led
    No open trial led
  93. 4 papers led
    No open trial led
  94. 4 papers led
    No open trial led
  95. 4 papers led
    No open trial led
  96. 4 papers led
    No open trial led
  97. 4 papers led
    No open trial led
  98. 4 papers led
    No open trial led
  99. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    4 papers led
    No open trial led
  100. 4 papers led
    No open trial led
  101. Technology Union Shenzhen Hospital

    深圳市南山区人民医院Shenzhen

    4 papers led
    No open trial led
  102. 4 papers led
    No open trial led
  103. 4 papers led
    No open trial led
  104. 4 papers led
    No open trial led
  105. 3 papers led
    No open trial led
  106. 3 papers led
    No open trial led
  107. 3 papers led
    No open trial led
  108. 3 papers led
    No open trial led
  109. 3 papers led
    No open trial led
  110. Chongqing General Hospital

    重庆大学附属中心医院(重庆市人民医院)Chongqing

    3 papers led
    No open trial led
  111. 3 papers led
    No open trial led
  112. 3 papers led
    No open trial led
  113. 3 papers led
    No open trial led
  114. 3 papers led
  115. 3 papers led
    No open trial led
  116. 3 papers led
    No open trial led
  117. 3 papers led
    No open trial led
  118. 3 papers led
    No open trial led
  119. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    3 papers led
    No open trial led
  120. 3 papers led
    No open trial led
  121. 3 papers led
    No open trial led
  122. 3 papers led
    No open trial led
  123. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    3 papers led
    No open trial led
  124. 3 papers led
    No open trial led
  125. 3 papers led
    No open trial led
  126. Wuzhou Red Cross Hospital

    梧州市红十字会医院Wuzhou

    3 papers led
    No open trial led
  127. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    3 papers led
  128. 3 papers led
    No open trial led
  129. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    3 papers led
    No open trial led
  130. Zhuhai People's Hospital

    珠海市人民医院Zhuhai

    3 papers led
    No open trial led
  131. Zibo Central Hospital

    淄博市中心医院Zibo

    3 papers led
    No open trial led
  132. 2 papers led
    No open trial led
  133. 2 papers led
    No open trial led
  134. 2 papers led
    No open trial led
  135. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    2 papers led
    No open trial led
  136. 2 papers led
    No open trial led
  137. 2 papers led
    No open trial led
  138. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    2 papers led
    No open trial led
  139. 2 papers led
    No open trial led
  140. 2 papers led
    No open trial led
  141. 2 papers led
    No open trial led
  142. 2 papers led
    No open trial led
  143. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    2 papers led
  144. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    2 papers led
    No open trial led
  145. 2 papers led
    No open trial led
  146. 2 papers led
    No open trial led
  147. 1 paper led
    No open trial led
  148. 1 paper led
    No open trial led
  149. 1 paper led
    No open trial led
  150. 1 paper led
    No open trial led
  151. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    1 paper led
    No open trial led
  152. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    1 paper led
    No open trial led
  153. Hunan Provincial People's Hospital

    湖南省人民医院(湖南师范大学附属第一医院)Changsha

    1 paper led
    No open trial led
  154. 1 paper led
    No open trial led
  155. 1 paper led
    No open trial led
  156. 1 paper led
    No open trial led
  157. 1 paper led
    No open trial led
  158. 1 paper led
    No open trial led
  159. 1 paper led
    No open trial led
  160. 1 paper led
    No open trial led
  161. West China Hospital of Stomatology

    四川大学华西口腔医院Chengdu

    1 paper led
    No open trial led
  162. 1 paper led
    No open trial led
  163. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    1 paper led
    No open trial led
  164. 0 papers led
    No open trial led
  165. 0 papers led
    No open trial led
  166. 0 papers led
    No open trial led
  167. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    0 papers led
    No open trial led
  168. 0 papers led
    No open trial led
  169. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  170. Ganzhou Cancer Hospital

    赣州市肿瘤医院Ganzhou

    0 papers led
    No open trial led
  171. Guangzhou Panyu Central Hospital

    广州医科大学附属番禺中心医院Guangzhou

    0 papers led
    No open trial led
  172. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    0 papers led
    No open trial led
  173. 0 papers led
    No open trial led
  174. 0 papers led
    No open trial led
  175. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    0 papers led
    No open trial led
  176. Nanxishan Hospital

    广西壮族自治区南溪山医院Guilin

    0 papers led
    No open trial led
  177. 0 papers led
    No open trial led
  178. 0 papers led
    No open trial led
  179. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    0 papers led
    No open trial led
  180. Taizhou Hospital

    浙江省台州医院Taizhou

    0 papers led
  181. Tongde Hospital

    浙江省立同德医院Hangzhou

    0 papers led
    No open trial led
  182. Yishui Central Hospital

    临沂市中心医院Linyi

    0 papers led
    No open trial led
  183. Zhanjiang Central Hospital

    湛江中心人民医院Zhanjiang

    0 papers led
    No open trial led

By university or health system 60

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Sun Yat-sen University

    中山大学Guangzhou

    555 papers led
    6 hospitals
  2. Central South University (Xiangya)

    中南大学湘雅Changsha

    154 papers led
    5 hospitals
  3. Guangxi Medical University

    广西医科大学Nanning

    124 papers led
    6 hospitals
  4. Fujian Medical University

    福建医科大学Fuzhou

    118 papers led
    6 hospitals
  5. Fudan University

    复旦大学Shanghai

    80 papers led
    6 hospitals
  6. Southern Medical University

    南方医科大学Guangzhou

    79 papers led
    6 hospitals
  7. Guangzhou Medical University

    广州医科大学Guangzhou

    52 papers led
    6 hospitals
  8. Sichuan University (West China)

    四川大学华西Chengdu

    46 papers led
    3 hospitals
  9. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    45 papers led
    5 hospitals
  10. Guilin Medical University

    桂林医学院Guilin

    35 papers led
    1 hospital
  11. Nanjing Medical University

    南京医科大学Nanjing

    33 papers led
    6 hospitals
  12. Xiamen University

    厦门大学Xiamen

    31 papers led
    2 hospitals
  13. 29 papers led
    2 hospitals
  14. Wuhan University

    武汉大学Wuhan

    27 papers led
    3 hospitals
  15. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    24 papers led
    3 hospitals
  16. Nanchang University

    南昌大学Nanchang

    24 papers led
    5 hospitals
  17. Jinan University

    暨南大学Guangzhou

    22 papers led
    4 hospitals
  18. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    22 papers led
    6 hospitals
  19. Zhengzhou University

    郑州大学Zhengzhou

    22 papers led
    6 hospitals
  20. Guangdong Medical University

    广东医科大学Zhanjiang

    21 papers led
    1 hospital
  21. Nantong University

    南通大学Nantong

    20 papers led
    1 hospital
  22. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    19 papers led
    1 hospital
  23. Soochow University

    苏州大学Suzhou

    18 papers led
    6 hospitals
  24. Chongqing University

    重庆大学Chongqing

    17 papers led
    2 hospitals
  25. Kunming Medical University

    昆明医科大学Kunming

    17 papers led
    3 hospitals
  26. Wenzhou Medical University

    温州医科大学Wenzhou

    17 papers led
    6 hospitals
  27. Qingdao University

    青岛大学Qingdao

    16 papers led
    5 hospitals
  28. Southwest Medical University

    西南医科大学Luzhou

    15 papers led
    1 hospital
  29. Capital Medical University

    首都医科大学Beijing

    13 papers led
    6 hospitals
  30. Shandong First Medical University

    山东第一医科大学Jinan

    13 papers led
    5 hospitals
  31. Guizhou Medical University

    贵州医科大学Guiyang

    12 papers led
    2 hospitals
  32. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    12 papers led
    5 hospitals
  33. China Medical University (Shenyang)

    中国医科大学Shenyang

    11 papers led
    3 hospitals
  34. Jiangnan University

    江南大学Wuxi

    11 papers led
    1 hospital
  35. Shenzhen University

    深圳大学Shenzhen

    11 papers led
    5 hospitals
  36. Army Medical University

    陆军军医大学Chongqing

    10 papers led
    3 hospitals
  37. Chongqing Medical University

    重庆医科大学Chongqing

    10 papers led
    2 hospitals
  38. Peking University Health Science Center

    北京大学医学部Beijing

    10 papers led
    2 hospitals
  39. Shandong University

    山东大学Jinan

    10 papers led
    4 hospitals
  40. Xi'an Jiaotong University

    西安交通大学Xi'an

    10 papers led
    3 hospitals
  41. Xuzhou Medical University

    徐州医科大学Xuzhou

    9 papers led
    2 hospitals
  42. Bengbu Medical University

    蚌埠医科大学Bengbu

    8 papers led
    1 hospital
  43. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    8 papers led
    1 hospital
  44. Shantou University Medical College

    汕头大学医学院Shantou

    8 papers led
    1 hospital
  45. Tianjin Medical University

    天津医科大学Tianjin

    8 papers led
    2 hospitals
  46. Chengdu University

    成都大学Chengdu

    7 papers led
    1 hospital
  47. Air Force Medical University

    空军军医大学Xi'an

    5 papers led
    2 hospitals
  48. Anhui Medical University

    安徽医科大学Hefei

    4 papers led
    2 hospitals
  49. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    4 papers led
    1 hospital
  50. Ningxia Medical University

    宁夏医科大学Yinchuan

    4 papers led
    2 hospitals
  51. Jilin University

    吉林大学Changchun

    3 papers led
    1 hospital
  52. Tongji University

    同济大学Shanghai

    3 papers led
    3 hospitals
  53. Xinjiang Medical University

    新疆医科大学Urumqi

    3 papers led
    2 hospitals
  54. Hebei Medical University

    河北医科大学Shijiazhuang

    2 papers led
    1 hospital
  55. Jishou University

    吉首大学Jishou

    2 papers led
    1 hospital
  56. Nanjing University

    南京大学Nanjing

    2 papers led
    1 hospital
  57. Naval Medical University

    海军军医大学Shanghai

    2 papers led
    1 hospital
  58. 2 papers led
    1 hospital
  59. 2 papers led
    1 hospital
  60. Harbin Medical University

    哈尔滨医科大学Harbin

    1 paper led
    1 hospital

168

open trials on nasopharyngeal carcinoma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 143 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT06059261

    Age 18 years to 65 years (registered criteria)

    Led by Chongqing University Cancer HospitalChongqing

  2. Recruiting
    Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT06796270

    Age 18 years to 75 years (registered criteria)

    Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou

  3. Recruiting
    International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07013461

    Age 18 years to Not stated (registered criteria)

    Led by The University of Hong Kong–Shenzhen HospitalShenzhen

  4. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07235319

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning

  5. Recruiting
    LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07325539

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen

  6. Recruiting
    MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07331428

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  7. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07332247

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  8. Recruiting
    Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07362979

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang

  9. Recruiting
    IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07376603

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  10. Recruiting
    A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07392320

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  11. Recruiting
    Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07459296

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  12. Recruiting
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07496190

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  13. Recruiting
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07528183

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan

  14. Recruiting
    Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07559877

    Age 18 years to 75 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  15. Recruiting
    Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07567742

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  16. Recruiting
    Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07584499

    Age 2 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  17. Recruiting
    Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07625423

    Age 18 years to 65 years (registered criteria)

    Led by West China HospitalChengdu

  18. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  19. Recruiting
    Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07705243

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  20. Recruiting
    Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07706985

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  21. Recruiting
    Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07781358

    Age 18 years to 80 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  22. Recruiting
    Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07796789

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou

  23. Recruiting
    Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07819656

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  24. Recruiting
    CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06095154

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  25. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  26. Recruiting
    Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06752239

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  27. Recruiting
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06788002

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

  28. Recruiting
    EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06802835

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  29. Recruiting
    Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06811844

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen University; 1 listed hospital as study siteHaikou, Xiamen

  30. Recruiting
    Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06831357

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  31. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  32. Recruiting
    GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06851247

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  33. Recruiting
    Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06870435

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  34. Recruiting
    Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06912698

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  35. Recruiting
    TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06912711

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  36. Recruiting
    A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06976190

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  37. Recruiting
    Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT07000643

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  38. Recruiting
    A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07035626

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  39. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  40. Recruiting
    Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07085234

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  41. Recruiting
    Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT07085988

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  42. Recruiting
    Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07101744

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  43. Recruiting
    Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07136519

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  44. Recruiting
    Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07137052

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  45. Recruiting
    Adaptive Immunotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07154069

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  46. Recruiting
    Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177443

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  47. Recruiting
    Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07188584

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  48. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  49. Recruiting
    Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07277764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  50. Recruiting
    Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07303023

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai

  51. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  52. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  53. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  54. Recruiting
    Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07340515

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  55. Recruiting
    Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07581821

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  56. Recruiting
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT05941741

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning

  57. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  58. Recruiting
    The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06182657

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  59. Recruiting
    Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06194656

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  60. Recruiting
    Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06197776

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  61. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  62. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  63. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  64. Recruiting
    A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06241599

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  65. Recruiting
    Individualized Elective Neck Irradiation in NPC Patients
    Phase
    Phase 3
    Started
    2024-04
    Registry
    NCT06241612

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  66. Recruiting
    Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06277050

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer Hospital; 2 listed hospitals as study sitesGanzhou, Nanchang

  67. Recruiting
    A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06287788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  68. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  69. Recruiting
    Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06307314

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  70. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  71. Recruiting
    De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06313450

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  72. Recruiting
    Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06321939

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  73. Recruiting
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06323239

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  74. Recruiting
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06349889

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen

  75. Recruiting
    Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06389201

    Age 20 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  76. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06437522

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  77. Recruiting
    Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06438627

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  78. Recruiting
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06445088

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan

  79. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

  80. Recruiting
    Deep Learning-based sbORN Diagnostic Model
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06463392

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  81. Recruiting
    Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06472713

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  82. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06475300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  83. Recruiting
    Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06509009

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  84. Recruiting
    Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06516133

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  85. Recruiting
    Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06533267

    Age 18 years to 75 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  86. Recruiting
    Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06611150

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  87. Recruiting
    Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06675214

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  88. Recruiting
    SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06676722

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  89. Recruiting
    "Xijiang Project" Screening Cohort for NPC
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06787456

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  90. Recruiting
    A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06829147

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  91. Recruiting
    Trop2-targeted immunoPET Imaging of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Registry
    NCT06851663

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  92. Recruiting
    CD70-targeted immunoPET Imaging of Malignant Cancers
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06852638

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  93. Recruiting
    Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05854849

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  94. Recruiting
    Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05860868

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  95. Recruiting
    Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05877872

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  96. Recruiting
    Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05884983

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  97. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

  98. Recruiting
    Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994170

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  99. Recruiting
    Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06017895

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  100. Recruiting
    GNT Induction Treatment in Locally Advanced NPC
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06026878

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  101. Recruiting
    Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06092957

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  102. Recruiting
    Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177301

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  103. Recruiting
    Xerostomia-optimised IMRT Versus Standard IMRT in NPC
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06282497

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  104. Recruiting
    Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06688760

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  105. Recruiting
    Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 1
    Started
    2023-07
    Registry
    NCT06886347

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  106. Recruiting
    18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT04813705

    Age 18 years to 80 years (registered criteria)

    Led by Taizhou HospitalTaizhou

  107. Recruiting
    Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05147844

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  108. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  109. Recruiting
    Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05342792

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  110. Recruiting
    Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-06
    Registry
    NCT05352321

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou

  111. Recruiting
    Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05397769

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  112. Recruiting
    Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05447169

    Age 30 years to 62 years; men only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  113. Recruiting
    Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05508347

    Age 18 years to 70 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  114. Recruiting
    Radiotherapy Combined With Endostatin and Capecitabine for NPC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05514275

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  115. Recruiting
    Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05527470

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou

  116. Recruiting
    SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05652192

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  117. Recruiting
    Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05707819

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  118. Recruiting
    Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-12
    Registry
    NCT05717790

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan

  119. Recruiting
    Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT06529562

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  120. Recruiting
    Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-08
    Registry
    NCT07327216

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  121. Recruiting
    Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
    Phase
    Phase 3
    Started
    2021-08
    Registry
    NCT04436965

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  122. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  123. Recruiting
    Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-06
    Registry
    NCT04944914

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  124. Recruiting
    ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT05062005

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  125. Recruiting
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05126160

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan

  126. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

  127. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  128. Recruiting
    Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04085900

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteWuzhou, Zhongshan

  129. Recruiting
    Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-06
    Registry
    NCT04376866

    Age 18 years to 65 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  130. Recruiting
    Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2020-06
    Registry
    NCT04425265

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  131. Recruiting
    Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04437329

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhou

  132. Recruiting
    Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04448522

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan

  133. Recruiting
    Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-07
    Registry
    NCT04453813

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  134. Recruiting
    Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-09
    Registry
    NCT04453826

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  135. Recruiting
    Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04544969

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  136. Recruiting
    To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2020-06
    Registry
    NCT04547673

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  137. Recruiting
    Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2018-01
    Registry
    NCT03919552

    Age 18 years to 64 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  138. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

  139. Not yet recruiting
    Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07064902

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen

  140. Not yet recruiting
    Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07268690

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  141. Not yet recruiting
    Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07303283

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  142. Not yet recruiting
    Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07388758

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  143. Not yet recruiting
    GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07540390

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  144. Not yet recruiting
    Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07756190

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  145. Not yet recruiting
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764887

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan

  146. Not yet recruiting
    A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07783321

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  147. Not yet recruiting
    Platinum-Free Regimen in Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07794488

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  148. Not yet recruiting
    A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07797881

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  149. Not yet recruiting
    A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07818486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChongqing, Guangzhou

  150. Not yet recruiting
    Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07824856

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  151. Not yet recruiting
    Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07902713

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  152. Not yet recruiting
    Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07918755

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan

  153. Not yet recruiting
    Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT05912582

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  154. Not yet recruiting
    GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06605131

    Age 6 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  155. Not yet recruiting
    PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06900218

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  156. Not yet recruiting
    A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2025-07
    Registry
    NCT07062484

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  157. Not yet recruiting
    Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07072000

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang

  158. Not yet recruiting
    Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06095167

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  159. Not yet recruiting
    KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06370026

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  160. Not yet recruiting
    Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06680115

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  161. Not yet recruiting
    Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06752382

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  162. Not yet recruiting
    A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05780294

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  163. Not yet recruiting
    Umbrella Biomarker-Guided Therapy in NPC
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT04605562

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  164. Not yet recruiting
    A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT05622474

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  165. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

  166. Not yet recruiting
    An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
    Phase
    Phase 2/Phase 3
    Started
    2021-07
    Registry
    NCT04890522

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  167. Enrolling by invitation
    Prognostic Value of TIL in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06763640

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  168. Enrolling by invitation
    IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06688175

    Age 65 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions